ZEJULA is the only PARP inhibitor that has demonstrated a clinically meaningful increase in progression-free survival (PFS) in women with recurrent ovarian cancer, regardless of BRCA mutation or biomarker status, in a randomized, prospectively designed Phase 3 clinical trial. ZEJULA offers oral, once-daily dosing, enabling convenient administration for maintenance treatment.
3D Molecular Visualization
This is a 3D molecular visualization of Poly(ADP-ribose) Polymerase (PARP1) bound by its inhibitor Zejula.
Purchase 3D print
If you’d like to purchase a 3D print of PARP1 bound by Zejula, then please visit our shapeways.com store where you can purchase a 3D print directly. Models are available in multiple sizes. Please contact us if you’d like to request something specific.